Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Catherine Wittgen

Vascular Surgery Saint Louis, MO Medical Doctor

NPI 1184728305 CMS profile 144948

1225 S Grand Blvd, Provider Enrollment, Saint Louis, MO 63104

Open in the dashboard

General payments

$138,556

195 records reported · program years 2019–2025

Research payments

$3,150

Paid to them · 4 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Catherine Wittgen of Saint Louis, MO is reported in the CMS Open Payments database as having received $138,556 across 195 general payments and $3,150 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,383 4
2024 General $166 2
2024 Research $613 1
2023 General $132 4
2023 Research $2,538 3
2022 General $40,109 46
2021 General $10,755 9
2020 General $18,514 26
2019 General $67,497 104

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Catherine Wittgen
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Catherine Wittgen were reported at $1,383. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Catherine Wittgen Vascular Surgery median Middle half National median
2019 $67,497 $796 $226–$2,363 $163
2020 $18,514 $348 $118–$1,110 $114
2021 $10,755 $471 $158–$1,421 $132
2022 $40,109 $725 $222–$2,183 $149
2023 $132 $836 $257–$2,440 $160
2024 $166 $909 $252–$2,619 $164
2025 $1,383 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. CVRx, Inc. $67,776 28 payments
  2. Organogenesis Inc. $64,116 117 payments
  3. E.R. Squibb & Sons, L.L.C. $3,510 2 payments
  4. Penumbra, Inc. $630 5 payments
  5. W. L. Gore & Associates, Inc. $599 11 payments
  6. Vascular Technology, Inc. $400 1 payment
  7. CryoLife, Inc. $178 3 payments
  8. Abbott Laboratories $147 1 payment
  9. Inari Medical, Inc. $138 1 payment
  10. Orthofix Medical, Inc. $138 1 payment
  11. Other $925 25 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $74,415 28 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $49,348 87 payments
  3. Travel and Lodging $8,265 25 payments
  4. Honoraria $3,450 3 payments
  5. Food and Beverage $3,078 52 payments
Products named General payments · program years 2019–2025
  1. Barostim Neo System $67,776 28 payments
  2. Apligraf $33,048 81 payments
  3. Puraply/Affinity/NuTech $33,048 81 payments
  4. Dermagraft $33,048 81 payments
  5. Puraply $30,067 35 payments
  6. ELIQUIS $3,510 2 payments
  7. Puraply Antimicrobial $1,000 1 payment
  8. Indigo System $389 3 payments
  9. C3 Delivery System $367 6 payments
  10. Indigo $241 2 payments
  11. Other $2,036 42 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. CVRx, Inc. $3,150 4 payments

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

81

Median for Vascular Surgery: 122

Drug cost

$863

Median for Vascular Surgery: $14,135

Branded share of claims

19.8%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Cilostazol Generic 43 $525
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 16 $209
Gabapentin Generic 22 $129

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 65 billing codes

Paid by Medicare

$44,227

Medicare's payments for the services billed

Medicare patients

130

Average age 70

Services billed

338

54 women, 76 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 51%
Heart failure 48%
Ischemic heart disease 48%
Diabetes 42%
Chronic kidney disease 42%
COPD 42%
Depression 39%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

199 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record